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SConclusions: Temporal change of PSS might be different between SES, non-SES, and
BMSuntil the 20thmonth of stent implantation.After the 20thmonth of stent implantation,
abnormal vessel reactions appeared to continue in some lesions after SES implantation.
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Background: There are limited data on whether delayed late catch-up exists in
sirolimus-eluting stents (SES) and bare-metal stents (BMS). We sought to compare
differences in time course of late loss (LL) between SES and BMS.
Methods: Serial (8-months, 2-years, and over 3-years) angiographic examination was
performed in 598 lesions treated with SES (n¼353) or BMS (n¼245). Lesions with 8-
months and 2-years instent-restenosis (>50% of angiographic diameter stenosis) were
excluded. LL was categorized as early (between post-procedure and 8-months),
delayed (between 8-months and 2-years), further delayed (between 2-years and over 3-
years) or overall (between post-procedure and over 3-years).
Results: Whereas early LL was signiﬁcantly smaller in SES than in BMS, delayed LL
was signiﬁcantly greater in SES than in BMS. On the other hand, further delayed LLwas
comparable between the 2 stents. Consequently, overall LL was signiﬁcantly smaller in
SES than in BMS. Moreover, the incidence of over 3-year instent-restenosis was similar
between the 2 stents (1.13 and 0.82% in SES and BMS, p¼0.70). In multivariate
analysis, stent type predicted delayed LL but did not predict further delayed LL.
Conclusions: SES lumen diameter progressively narrowed in delayed phase
compared with BMS. However, the narrowing rate was similar among SES and BMS
over 2 years. This evidence may raise the possibility that the impact of late catch-up
phenomenon on SES restenosis over 2 years is minimal.TCT-464
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Background: The morphological characteristics of restenotic tissue with bare metal
stent (BMS) in very late in-stent restenosis (VL-ISR) were different from those in early
in-stent restenosis (E-ISR) and similar to atherosclerotic plaque which is called neo-
atherosclerosis. However, the efﬁcacy of cutting balloon angioplasty (CBA) for those
different tissues has not been analyzed. The purpose of this study is to compare the
efﬁcacy of CBA for ISR of BMS according to the morphologic pattern of restenosis.
Methods: Patients with ISR of BMSwere enrolled and were performed optical coherence
tomography before intervention. According to the optical coherence tomography (OCT)
images and periods after stent implantation, those patients were categorized to 2 group; 1)
Neoatherosclerosis group (n¼38); angiographcial restenosiswas revealed later than5 years
after stent implantation without restenosis within the ﬁrst year and lipid-like image was
shown by OCT image; 2) neointimal hyperplasia (NIH) group (n¼62); angiographical
restenosis was revealedwithin ﬁrst year andOCT image showed homogeneous intima. All
cases were treated with CBA and 6months follow-up angiography was performed and the
angiographic ﬁndings at 6 months follow-up were compared between the 2 groups.
Results: At 6 months angiographic follow-up, the frequency of re-ISR and target
lesion revascularization were signiﬁcantly higher in neoatherosclerosis group (57.8%
vs 35.4%, 44.7% vs 24.2%; p<0.05). Re-occlusion was revealed only 1 case in
neoahterosclerosis group (p¼0.31). There was no signiﬁcant differences about late
loss (0.870.56mm vs 0.740.75mm, p¼0.39).
Conclusions: The treatment with CBA for BMSVL-ISR lesion with neoatherosclesosis
could not show similar efﬁcacy compare to those for BMSE-ISR lesion with NIH tissue.B142 JACC Vol 62/18/Suppl B j October 27–November 1, 20TCT-465
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Background: Although stents form the backbone of PCI, they may not be ideal
for all lesions, especially; in-stent restenosis (ISR) and diffuse disease in small
vessels. Drug-eluting balloons (DEB) are emerging as an alternative treatment in
such situations and their use is escalating. DEBs have been studied in randomized
trials and registry studies with favourable outcomes. Despite these studies, data
from real-world population is lacking. We report a single-center experience of
DEB in the treatment of ISR and de novo coronary artery disease from a large
cohort of patient.
Methods: We retrospectively evaluated all patients treated with the drug-eluting
balloon (In.Pact FalconTM, Medtronic Inc., Minneapolis, MN, USA) between January
2009 and December 2011. The measured endpoints were cardiac death, MI, target
lesion revascularization (TLR), target vessel revascularization (TVR) and major
adverse cardiac events (MACE) deﬁned as combination of cardiac death, MI and
TVR.
Results: A total of 7622-PCI procedures were carried out at our centre during the
study period. Drug-eluting balloons were used in 275-lesions (184-patients) (3.6%).
The predominant indication for DEB use was ISR (n¼170, 62%), with de novo lesions
accounting for the remainder (n¼105, 38%). The mean age of patients treated with
DEB was 66.29.6 years and 87% were male. Bailout stenting was required in 31.6%
of lesions; 24% for angiographic optimization and 7.3% for dissection caused by
balloon injury. The median clinical follow-up was 14.6 months (IQR 12-23) and
a minimum of 6-months follow-up was achieved in all patients. The rates of cardiac
death, MI, TLR, TVR and MACE were: 3.8%, 1.6%, 16.8%, 17.9% and 21.7%
respectively. The overall rate of stent thrombosis was 0.5% (n¼1). Further sub-
analysis revealed that the beneﬁts of DEB use were more pronounced in BMS-ISR
than DES-ISR (TLR: 11% vs. 17.7%, TVR: 11% vs. 22%, MACE: 15% vs. 28%)
respectively.
Conclusions: Our results suggests that DEB can be considered in lesions where the
use of stents are not desirable especially restenotic lesions and diffuse small vessel
disease. Further long-term follow-up of these patients, will provide us more insights
on the long-term outcomes.
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Background: It has not been reported about the efﬁcacy of paclitaxel-coated balloon
for in-stent restenosis in patients with renal failure on hemodialysis.
Methods: From January 2003 to August 2012, 359 in-stent restenosis lesions in
patients with renal failure on hemodialysis underwent percutaneous coronary inter-
vention. One hundred sixty one lesions (56 lesions treated with paclitaxel-coated
balloon, 105 lesions treated with drug-eluting stent) underwent midterm follow-up
coronary angiography by 8 months after treatment. We compared the quantitative
coronary analysis data and the rates of restenosis and target lesion revascularization
(TLR) at midterm f/u between paclitaxel-coated balloon group and drug-eluting stent
group.
Results: There were no signiﬁcant difference in the rates of restenosis and TLR. The
minimal luminal diameter at midterm f/u showed no signiﬁcant difference between
two groups, but the late loss was signiﬁcantly small in paclitaxel-coated balloon
group. Data are shown in the table.
Conclusions: The treatment with paclitaxel-coated balloon has the equivalent efﬁcacy
of treatment with drug-eluting stent for in-stent restenosis in patients with renal failure
on hemodialysis.13 j TCT Abstracts/POSTER/In-stent Restenosis and Stent Thrombosis
